Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NDBR 101 vaccine for tularemia prevention
NCT00787826Phase 2Unknown
- Sponsor
- U.S. Army Medical Research and Development Command
- Start
- Aug 2009
- Primary completion
- Nov 2019
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of NDBR 101 in tularemia, sponsored by U.S. Army Medical Research and Development Command. Primary endpoints: Adverse Events at 5 years, Erythematous papule, vesicle, and/or eschar at 7 days and 1 more. Status: unknown.
02
Drugs
NDBR 101
03
Conditions
tularemia
Beyond the preview
Go deeper on NCT00787826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00787826.